The Business Research Company’s report on the Gastroesophageal Reflux Disease Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the gastroesophageal reflux disease therapeutics market’s growth in recent years?
The prevalence of gastroesophageal reflux disease is expected to propel the growth of the gastroesophageal reflux disease therapeutics market moving forward. Gastroesophageal reflux disease is a chronic condition characterized by the backflow of stomach acid into the esophagus, causing symptoms such as heartburn, regurgitation, and potential complications. The gastroesophageal reflux disease (GERD) therapeutics help in reducing and managing the symptoms of acid reflux by neutralizing the pH of the gut, controlling inflammation, and improving esophageal function. For instance, in September 2022, according to the article published by WebMed, a US-based online publisher of news and information about human health, more than 60 million American adults suffer heartburn at least once a month, and more than 15 million suffer daily. Furthermore, in July 2022, statistics shared by the National Library of Medicine, a US-based federal medical library, GERD is one of the most often diagnosed digestive illnesses in the United States, with a 20% prevalence, resulting in a significant economic burden in direct and indirect expenditures as well as a negative impact on quality of life. Therefore, the prevalence of gastroesophageal reflux disease is expected to drive the growth of the gastroesophageal reflux disease therapeutics market.
Access Your Free Sample of the Global Gastroesophageal Reflux Disease Therapeutics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp
How does the future projection of the gastroesophageal reflux disease therapeutics market size compare to its historical growth?
The gastroesophageal reflux disease therapeutics market size has grown steadily in recent years. It will grow from $5.93 billion in 2024 to $6.14 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to changing lifestyles and dietary habits, aging population, increased awareness and diagnosis, prevailing stressful lifestyles, rise in obesity rates
The gastroesophageal reflux disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $7.89 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rise in demand for novel therapies, growing geriatric population, personalized medicine approaches, focus on non-pharmacological interventions, emergence of biologics and innovative therapies. Major trends in the forecast period include alternative therapies and mind-body practices, expanded research into gut health, advent of patient-centric care models, targeted marketing for gerd awareness, integration of digital health tools.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12058&type=smp
Which key players are shaping the future of the gastroesophageal reflux disease therapeutics market?
Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited
What trends will propel the growth and evolution of the gastroesophageal reflux disease therapeutics market?
Product innovations are the key trend gaining popularity in the gastroesophageal reflux disease therapeutics market. Major companies operating in the gastroesophageal reflux disease therapeutics market are focusing on innovative medications to sustain their position in the market. For instance, in November 2023, Phathom Pharmaceuticals, a US-based biopharmaceutical company, launched VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, approved for the healing and maintenance of all grades of erosive esophagitis, as well as for alleviating heartburn associated with both erosive and non-erosive GERD. Clinical trials showed remarkable outcomes, with a healing rate of 93% in patients treated with the 20 mg dosage, compared to 85% for the standard proton pump inhibitor (PPI) lansoprazole.
Which regions are expected to become dominant players in the gastroesophageal reflux disease therapeutics market?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
What are the emerging key segments in the gastroesophageal reflux disease therapeutics market, and how are they evolving?
The gastroesophageal reflux disease therapeutics market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Super markets
4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis
Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12058
What defines the structure and scope of the gastroesophageal reflux disease therapeutics market?
Gastroesophageal reflux disease (GERD) therapeutics is a medication for chronic medical illness characterized by the upward movement of stomach contents into the esophagus that causes heartburn and regurgitation. The therapeutics are used to neutralize and reduce the production of stomach acid to maintain optimal pH in the gut and prevent the passage of fluids back into the stomach that cause acid reflux.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
